TMCI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Treace Medical Concepts Inc (TMCI) is not a strong buy at this time for a beginner investor with a long-term focus. While the company shows some revenue growth, its financial performance remains weak with consistent net losses, negative EPS, and declining gross margins. Additionally, there are no significant positive catalysts or trading signals to support a buy decision. The stock's technical indicators are mixed, with bearish moving averages and neutral RSI, suggesting no clear upward momentum. The options data also reflects a bearish sentiment, with a high put-call volume ratio. Given the lack of strong positive drivers and the investor's long-term focus, it is better to hold off on investing in TMCI at this time.
The MACD is positive and expanding, indicating potential upward momentum. However, the RSI is neutral at 62.99, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), suggesting a lack of sustained upward trend. Key resistance levels are at 2.06 and 2.128, with support at 1.838 and 1.77.
Revenue growth of 11.37% YoY in Q3 2025, and a 46% reduction in cash usage for the full year 2025.
Consistent net losses, negative EPS, declining gross margins, and bearish sentiment in options trading (high put-call volume ratio). Analysts have lowered the price target, and there are no significant insider or hedge fund trading trends.
In Q3 2025, revenue increased by 11.37% YoY to $50.21 million, net income improved slightly but remained negative at -$16.29 million, and EPS increased to -0.26. Gross margin declined to 79.07%, down 1.34% YoY. For the full year 2025, revenue was $212.7 million, but the company reported a net loss of $59 million.
Truist analyst Richard Newitter lowered the price target from $4 to $3 and maintained a Hold rating. The analyst is cautiously optimistic about the MedTech sector but sees TMCI as lacking near-term catalysts for durable revenue acceleration.
